La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ortin Global Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Ortin Global ha un patrimonio netto totale di ₹28.2M e un debito totale di ₹18.0M, che porta il suo rapporto debito/patrimonio netto a 63.8%. Le sue attività totali e le sue passività totali sono rispettivamente ₹65.9M e ₹37.7M.

Informazioni chiave

63.8%

Rapporto debito/patrimonio netto

₹18.02m

Debito

Indice di copertura degli interessi	n/a
Contanti	₹23.43m
Patrimonio netto	₹28.24m
Totale passività	₹38.40m
Totale attività	₹66.64m

Aggiornamenti recenti sulla salute finanziaria

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Dec 27

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Sep 15

Recent updates

Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention Today

Jan 24

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Dec 27

Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Nov 30

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Sep 15

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( ₹63.4M ) di ORTINLAB superano le sue passività a breve termine ( ₹20.4M ).

Passività a lungo termine: Le attività a breve termine di ORTINLAB ( ₹63.4M ) superano le sue passività a lungo termine ( ₹17.3M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ORTINLAB ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di ORTINLAB si è ridotto da 88.3% a 63.8% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ORTINLAB ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: ORTINLAB ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 16.6 % ogni anno

Ortin Global Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Recent updates

Ortin Global Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: ₹0.13 loss per share (vs ₹0.02 profit in 1Q 2024)

New minor risk - Share price stability

Ortin Global Limited to Report Q1, 2025 Results on Aug 13, 2024

Ortin Laboratories Limited Announces Resignation of Divya Purswani as Company Secretary and Compliance Officer

Full year 2024 earnings released: ₹9.89 loss per share (vs ₹0.12 loss in FY 2023)

Ortin Laboratories Limited to Report Q4, 2024 Results on May 30, 2024

Third quarter 2024 earnings released: ₹3.43 loss per share (vs ₹0.56 profit in 3Q 2023)

Ortin Laboratories Limited Appoints Divya Purswani as Company Secretary and Compliance Officer

Ortin Laboratories Limited to Report Q3, 2024 Results on Feb 13, 2024

Now 22% overvalued after recent price rise

Insufficient new directors

Second quarter 2024 earnings released

Ortin Laboratories Limited Announces Executive Changes

Ortin Laboratories Limited Appointment of Harish Sharma as Company Secretary

Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released

Ortin Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

Drugs Control Administration, Government of Telangana Cancels Manufacturing License of Ortin Laboratories Limited

Ortin Laboratories Limited Announces Resignation of Nitesh Kumar Sharma as Company Secretary/Compliance Officer

New minor risk - Share price stability

Full year 2023 earnings released: ₹0.08 loss per share (vs ₹0.49 loss in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.11 loss in 3Q 2022)

Ortin Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ortin Laboratories Limited Announces Resignation of J R K Panduranga Rao as Independent Director

Second quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.07 in 2Q 2022)

Ortin Laboratories Limited to Report First Half, 2023 Results on Nov 14, 2022

Ortin Laboratories Limited Announces Cessation of Bh. Satyanarayana Raju and G. Venkata Ramana, Directors

Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: ₹0.05 loss per share (vs ₹0.11 profit in 1Q 2022)

Ortin Laboratories Limited to Report Q1, 2023 Results on Aug 13, 2022

Full year 2022 earnings released: ₹0.49 loss per share (vs ₹1.16 profit in FY 2021)

Ortin Laboratories Limited to Report Q4, 2022 Results on May 30, 2022

Whole Time Director Sanka Mohan Murthy has left the company

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹1.16 (vs ₹0.69 loss in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Ortin Laboratories Limited to Report Q3, 2021 Results on Feb 13, 2021

Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Ortin Laboratories Limited Appoints Mr. S. Srinivas Kumar as CFO

Investor sentiment improved over the past week

New 90-day high: ₹30.00

Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?

Ortin Laboratories Limited Appoints Pottur Sujatha as Additional Director

Market bids up stock over the past week

Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

New 90-day high: ₹23.15

First quarter earnings released

Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load

Ortin Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

Ortin Laboratories Limited to Report Q4, 2020 Results on Jul 30, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane